Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | ALB | P02768 | 2/20 | 0.51 |
| ▸ | BLM | P54132 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | TK1 | P04183 | 2/20 | 0.43 |
| ▸ | TYMP | P19971 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4333741 | 1.00 | LMNA (0.51) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL4268524 | 1.00 | LMNA (0.51) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL4270554 | 1.00 | LMNA (0.51) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL4264216 | 1.00 | LMNA (0.51) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL4325656 | 1.00 | LMNA (0.51) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL4259439 | 1.00 | LMNA (0.51) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL4322230 | 0.88 | LMNA (0.47) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL4333796 | 0.88 | LMNA (0.47) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL4325119 | 0.88 | LMNA (0.47) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL4329091 | 0.88 | LMNA (0.47) | LMNAALBBLMALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227431-B2 | Nucleoside derivatives | HETERO DRUGS LIMITED (IN) | 2012-07-24 | — | — | US | disclosed |
| WO-2009115893-A2 | NOVEL NUCLEOSIDE DERIVATIVES | HETERO RESEARCH FOUNDATION (IN) | 2009-09-24 | — | — | WO | disclosed |
| US-20090233879-A1 | NOVEL NUCLEOSIDE DERIVATIVES | HETERO DRUGS LIMITED (IN) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233879-A1 | NOVEL NUCLEOSIDE DERIVATIVES | ENTPD5, PNP, ENTPD1 | LMNA 2060/4885ALB 4828/4885BLM 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.